New antibody cocktail aims to stop rabies after multiple dog bites

NCT ID NCT07624461

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new antibody injection, called zamerovimab and mazorelvimab, combined with the standard rabies vaccine, can prevent rabies in people who have been severely bitten by a dog. The trial follows 80 adults in China for up to one year to see if they stay rabies-free. The goal is to improve protection after high-risk exposures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zamerovimab and mazorelvimab injection (a human rabies antibody cocktail) plus rabies vaccine
What this could lead to
If successful, this could offer a more effective way to prevent rabies after severe dog bites, potentially saving lives in areas where rabies is common.
What could go wrong
This is a small, early real-world study with only 80 participants, so results may not apply to everyone. The treatment might not prevent rabies in all cases, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Disease Prevention and Control Center of Nanyang

    Nanyang, Henan, 473000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.